Register free for our breaking news email alerts with analysis and cutting edge commentary from our award winning team. Registration only takes a minute.
Please see terms and conditions for restrictions on use of Citywire's Fund Manager database.

This Fund Manager Rating is based on the Citywire Long Only ratings methodology

Citywire Ratings are rewarded for risk adjusted outperformance of benchmarks we select independently More information on how Ratings are calculated

Marcel Fritsch

Marcel Fritsch

Showing manager performance in Switzerland View performance globally

About Marcel Fritsch

Marcel Fritsch is a global analyst for medical technology & healthcare services and a senior portfolio manager at Bellevue Asset Management. He is a member of Bellevue’s Healthcare Funds & Mandates team and manages the BB Adamant Medtech & Services (Lux) fund and the BB Adamant Global Medtech & Services (CH) fund. Prior to joining Bellevue in 2008, he was a management consultant with Deloitte Touche Tohmatsu, where he advised multinational companies in the medical technology, pharmaceutical and manufacturing sectors on strategic and operational issues. Fritsch graduated from the University of St. Gallen (HSG), where he earned an MSc in economics.

Are you Marcel Fritsch?

Citywire Rating: AAA rated


  • JRated AA in Jun 2017
  • JRated AA in Jul 2017
  • ARated AA in Aug 2017
  • SRated AA in Sep 2017
  • ORated AA in Oct 2017
  • NRated AA in Nov 2017
  • DRated AA in Dec 2017


  • JRated AA in Jan 2018
  • FRated AA in Feb 2018
  • MRated AA in Mar 2018
  • ARated AAA in Apr 2018
  • MRated AAA in May 2018
  • JRated AAA in Jun 2018
  • JRated AAA in Jul 2018
  • ARated AAA in Aug 2018
  • SRated AAA in Sep 2018
  • ORated AAA in Oct 2018


Equity - Pharmaceuticals & Health Care
over : 30/09/2015 - 30/09/2018

Total Return

Month by Month Performance

Quarterly Performance

to 30/09/2018 Annual Q1 Q2 Q3 Q4
2018 2.4% 15.0% 11.9%
2017 25.9% 10.3% 6.0% 1.9% 5.7%
2016 5.0% -4.8% 9.8% 5.7% -5.0%
2015 0.3% 1.7% -6.6% -3.9% 9.9%
2014 32.9% 4.9% 3.3% 4.7% 17.1%
2013 6.7%

Related News

Bellevue AM launches health tech fund

Investors will now have access to tech stocks benefiting from the fundamentals of the healthcare sector.

AA-rated managers: how we’re playing the medtech sector

Bellevue AM's Stefan Blum and Marcel Fritsch reveal how they’re tapping developments in big data, cloud computing and robotics to deliver outperformance.

Citywire Discovery Source: Citywire Discovery Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated)..Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.